PARIS and OSAKA, Japan, May 18, 2011 /PRNewswire/ -- Cellectis bioresearch, a subsidiary
"In February 2011, we launched our revolutionary rapid, custom-designed TALEN service that enables access to genome customization tools to a large audience of life science researchers, due to its affordable price,” said Luc Selig, VP Sales & Marketing at Cellectis bioresearch. "We are now targeting rapid global distribution and Japan is a major player in life science research. Wako will allow us to enter this important market effectively, thanks to its key position."
Cellectis bioresearch's current portfolio includes more than 200 product references that address the genome customization requirements of life science researchers. In the last 12 months, Cellectis bioresearch has deployed its own sales force in Europe and the USA and has appointed agents and distributors in Canada and India. Online purchase is also available through the Cellectis bioresearch website.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.
The kits can be purchased online from www.cellectis-bioresearch.com. More information on the website.
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, bioresearch and agriculture. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.
More information at www.cellectis.com
Follow Cellectis on Twitter at www.twitter.com/cellectis
About Wako Pure Chemical Industries, Ltd.
Wako Pure Chemical Industries, Ltd., which is headquartered at Osaka (Japan) is the Japan's largest manufacture of laboratory chemical, specialty chemicals, and diagnostic reagents. Wako was founded in 1922 and currently has 1,440 employees, locating offices in all over in Japan, Europe and US. Wako contribute to the development of science and technology and create a prosperous future.
For further information, please go to: http://www.wako-chem.co.jp/english/
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
(1) TALEN: Transcription Activator-Like Effector Nucleases
Subscribe to our Free Newsletters!
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...
Bladder neck incision is a surgical procedure where cuts are made in the neck of the urinary ...View All